Cerebrolysin in acute ischemic stroke


Phase N/A Results

Trial Description

To assess the efficacy and safety of Cerebrolysin in patients with acute ischemic stroke.


  • Cerebrolysin Drug
    Intervention Desc: Prepared by enzymatic breakdown of lipid-free pig brain products. Consists of 85% free amino acids and 15% biologically active small peptides. Mechanism not certain.

Trial Design

Double-blind, placebo-controlled trial of 48 patients at a single center.

Patient Involvement

Patients were randomized to receive intravenous infusion therapy with placebo or Cerebrolysin (20 ml/day) for 20 days. Treatment was initiated within 12 h (mean 7.8 ± 3.7 h) after the onset of first symptoms. Efficacy visits were performed on days 1, 5, 10, and 20. A follow-up examination was carried out 2 months after end of treatment.


Type Measure Time Frame Safety Issue
Primary Barthel Index (BI), Graded Neurological Scale (GNS), Clinical Global Impression (CGI) and Physiology Hemiplegia Assessment (PHA).